Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis |
| |
Authors: | Liang Wenhua Wang Dongping Ling Xiaoting Kao Andrew Allen Kong Yuan Shang Yushu Guo Zhiyong He Xiaoshun |
| |
Affiliation: | Organ Transplant Center, First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan Er Road, Guangzhou, China. |
| |
Abstract: | Sirolimus (SRL) is a novel immunosuppressant with antitumor properties. We performed a meta-analysis to determine whether SRL can improve patient survival and decrease the risks of tumor recurrence in patients with a pretransplant diagnosis of hepatocellular carcinoma (HCC). We searched databases for controlled clinical trials assessing the survival and oncological benefits of SRL for liver transplant recipients with pretransplant HCC. Five studies with a total of 2950 participants were included in this study. In comparison with SRL-free regimens, SRL-based regimens improved overall survival at 1 [odds ratio (OR) = 4.53, 95% confidence interval (95% CI) = 2.31-8.89], 3 (OR = 1.97, 95% CI = 1.29-3.00), and 5 years (OR = 2.47, 95% CI = 1.72-3.55). The pooled results showed that in comparison with SRL-free regimens, SRL-based regimens decreased tumor recurrence (OR = 0.42, 95% CI = 0.21-0.83). No significant differences in the frequencies of episodes of major posttransplant complications were observed between the groups. In conclusion, SRL is generally safe and prolongs patient survival in liver transplant recipients with pretransplant HCC. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|